Brookline Capital Markets Estimates SABS Q3 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities researchers at Brookline Capital Markets upped their Q3 2026 earnings per share estimates for shares of SAB Biotherapeutics in a research note issued to investors on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($0.24) per share for the quarter, up from their previous estimate of ($0.25). The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.21) per share. Brookline Capital Markets also issued estimates for SAB Biotherapeutics’ Q4 2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at $0.48 EPS.

A number of other research analysts also recently weighed in on SABS. Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 target price for the company. Leerink Partners increased their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, June 15th. Wall Street Zen raised SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. Barclays assumed coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price on the stock. Finally, Weiss Ratings cut SAB Biotherapeutics from a “sell (d+)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, SAB Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $12.00.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.76 on Monday. The company’s fifty day simple moving average is $3.70 and its 200-day simple moving average is $3.83. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The firm has a market cap of $342.12 million, a PE ratio of -2.89 and a beta of 0.53. SAB Biotherapeutics has a 12 month low of $1.85 and a 12 month high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.28).

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Vivo Capital LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter valued at $22,954,000. Perceptive Advisors LLC increased its holdings in shares of SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after purchasing an additional 5,628,533 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of SAB Biotherapeutics in the third quarter valued at about $8,847,000. Woodline Partners LP acquired a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $5,730,000. Finally, Spruce Street Capital LP acquired a new stake in shares of SAB Biotherapeutics during the 4th quarter worth about $8,222,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.